Compare Icl Group Ltd (ICL) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Icl Group Ltd vs Illumina, Inc. — how do they compare? Icl Group Ltd trades at $5.1 (market cap $6.47B), while Illumina, Inc. trades at $269.18 (market cap $39.95B). The key difference: Illumina, Inc. is far larger — about 6.2× Icl Group Ltd's market cap, and Icl Group Ltd pays a 4.11% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Icl Group Ltd for 56 Days and Illumina, Inc. for 83 Days on average.
| ICL | ILMN | |
|---|---|---|
Market Cap | $6.47B | $39.95B |
Volume | 1,387,140 | 3,169,503 |
Sector | Basic Materials | Health |
52-Week High | $6.84 | $293.69 |
52-Week Low | $4.80 | $91.00 |
Typical Hold Time | 56 Days | 83 Days |
Enterprise Value | $9.11B | $41.31B |
Dividend Yield | 4.11% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ICL trades at $5.08 with no recent price movement. The stock shows mixed technical signals with a bearish overall trend but neutral oscillators. Fundamentally, the company reported $7.15B revenue in 2025 with a 3.95% net margin, while valuation ratios appear reasonable with P/E of 20.83 and P/S of 0.84. Recent earnings showed Q2 2026 beat expectations with $0.12 EPS versus $0.11 expected. The company maintains stable cash flow generation despite recent net cash outflows.
ICL presents a cautious opportunity with 19.7% upside to the $6.08 consensus price target, though analyst sentiment is neutral with 100% hold ratings. Key risks include fertilizer industry headwinds from higher input costs and competitive pressures. The dividend yield of approximately 1.2% provides income support while investors await earnings recovery toward projected 2026 profitability improvement.
Illumina (ILMN) trades at $267.76, down 2.11% today but remains near recent highs after a strong 94.9% YTD rally. The stock shows bullish technical momentum with recent earnings beats and improved profitability, with net income turning positive to $850 million in 2025 after previous losses. S&P 500 inclusion in September 2026 and growing AI integration in genomics provide positive catalysts, though valuation metrics remain elevated with a P/E of 49.36.
Outlook remains positive with analyst consensus favoring Buy ratings (54%) and a $241 price target, though current price exceeds consensus. Key opportunities include sequencing growth and AI adoption, while risks include China headwinds, margin pressure, and high valuation multiples requiring sustained execution to justify premium pricing.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
